Table 2. Patient cardiac and cancer medications according to Her2/ATC treatment status.

	AT	NAT	Total	P value
	N = 62 (%)	N = 54 (%)	N = 116 (%)
Cardiac Medications
Beta blocker	32(51.6)	36(66.7)	68(58.6)	0.146
ACEi/ARB	27(43.5)	20(37.0)	47(40.5)	0.603
Statins	27(43.5)	26(48.1)	53(45.7)	0.752
Nitrates	3(4.8)	2(3.7)	5(4.3)	0.888
Cancer therapy
Herceptin/Perjeta	27(43.5)	0(0.0)	27(23.3)	< .0001*
ICI	1(1.6)	0(0.0)	1(0.9)	1.000
Anthracycline	52(83.9)	0(0.0)	52(44.8)	< .0001*
TKI	6(9.7)	1(1.9)	7(6.0)	0.169
Radiation Therapy	51(82.3)	40(74.1)	91(78.4)	0.399
Other Cancer Therapies
PARP inhibitors	0(0.0)	0(0.0)	0(0.0)	1.000
Anti-Metabolites	9(14.5)	1(1.9)	10(8.6)	0.036*
SERMs/Anti-estrogens	32(51.6)	31(57.4)	63(54.3)	0.663
Platinum Agents	5(8.1)	0(0.0)	5(4.3)	0.094
Topoisomerase Inhibitors	0(0.0)	0(0.0)	0(0.0)	1.000
Proteasome Inhibitors	0(0.0)	3(5.6)	3(2.6)	0.196
Alkylating agents	30(48.4)	0(0.0)	30(25.9)	< .0001*
Taxanes	45(72.6)	0(0.0)	45(38.8)	< .0001*